tolperisone

Small moleculeexperimental

Tolperisone is a centrally acting skeletal muscle relaxant used for the treatment of increased muscle tone associated with neurological diseases. It has been used since the 1960s. — Wikipedia

Clinical trial activity

6 trials · 4 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Aug 1, 2006 (NCT00364039)

Timeline

2000s

Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Jan 1, 2007
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Sodium channel protein type II alpha subunitINHIBITOR
SCN2A inhibitor
- Sodium channel protein type 2 subunit alpha (SCN2A) ↗

Chemistry & pharmacology

Loading structure…

SMILES

Cc1ccc(C(=O)C(C)CN2CCCCC2)cc1

Mol. weight: 245.37 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Racemic Mixture
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

av650
dl-tolperisone
mideton
mydeton
mydeton
mydeton
mydetone
n-553 [as hydrochloride]
n-553 [as hydrochloride]
tolperisone
tolperisone
tolperisone
tolperisone
tolperisone
tolperisone
tolperisone
(+/-)-tolperisone
tolperisone hcl
tolperisone hcl
tolperisone hcl
tolperisone hydrochloride
tolperisone hydrochloride

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT04465266	Phase 1	Jul 28, 2020	Neurana Pharmaceuticals, Inc.
NCT03802565	Phase 2	Feb 1, 2019	Neurana Pharmaceuticals, Inc.
NCT00531466	Phase 2	Sep 1, 2007	Avigen, Thomas Jefferson University
NCT00532532	Phase 2	Sep 1, 2007	Avigen
NCT00456560	Phase 1	Apr 1, 2007	Avigen
NCT00364039	Phase 1	Aug 1, 2006	Avigen, Shin Nippon Biomedical Laboratories

Showing 6 of 6 trials

Page 1 / 1

Organizations

Research & Development (4)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Avigen	For profit	4	4	2	2006
Neurana Pharmaceuticals, Inc.	For profit	2	2	2	2019
Shin Nippon Biomedical Laboratories	For profit	1	0	1	2006
Thomas Jefferson University	Academic/Hospital	1	0	1	2007

4 organizations

Page 1 / 1